ClinicalTrials.gg
CompletedNCT03044132Updated Sep 6, 2019

DermACELL AWM® in Chronic Wagner Grade 3/4 Diabetic Foot Ulcers

An interventional study of DermACELL AWM in Diabetic Foot Ulcer and Lower Extremity Wound, sponsored by LifeNet Health. Completed at 2 sites in United States. Open to participants aged 21 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-09-06.

Sponsored by LifeNet Health · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Not applicable
Ages
21 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Enrollment
158th of 322
61 · median 60
Started
2017
with 19 others
No phase
186 of 381
38 open now
Registered
174th of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 158th largest by enrollment of the 322 interventional ones that give a count, is one of 20 that started in 2017, is one of 186 with no phase, and was the 174th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 21 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, multicenter, clinical research trial evaluating the clinical outcomes of DermACELL AWM in dermal regeneration.

Read the detailed description

This clinical evaluation with DermACELL AWM will explore its use in the treatment of complex soft tissue defects involving muscle, fascia, tendon, or bone exposure (Wagner Classification 3 and 4).

A total of 50 subjects will be treated with DermACELL AWM in the operating room for coverage of deep soft tissue defects in the lower extremity. Subjects will then be followed in the outpatient clinic for up to 16 weeks.

The specific aim of the study is to assess the ability of the product to sustain an optimal dermal layer. The time (days) required for wound bed preparation (granular bed after placement of DermACELL AWM) and safety data will be collected.

03

Conditions studied

  • Diabetic Foot Ulcer
  • Lower Extremity Wound

Browse trials for

Keywords

  • Diabetic Foot Ulcer
  • DFU
  • Lower Extremity Wound
  • Skin Substitute
04

Who can participate

Ages eligible
21 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Wagner Grade 3 or 4 complex soft tissue defect that extends below subcutaneous tissue (exposed fascia, ligament, tendon, muscle, or bone)
  • target wound that is either acute or chronic (nonhealing wounds greater than 4 weeks but not greater than 1 year in duration)
  • target wound that is not amendable to primary closure
  • target wound deemed without any residual infection (as assessed by Investigator) or is being treated upon entry into the clinical trial
  • adequate perfusion to the extremity
  • laboratory assessments which represent a good potential for wound healing (liver and kidney function, nutritionally stable and diabetes control)

Exclusion criteria

Exclusion Criteria:

  • untreated infection of soft tissue or bone
  • untreated connective tissue disorders
  • (BMI) of ≥ 50
  • undergoing chemotherapy/radiation therapy or taking an medication
  • active liver disease (e.g. hepatitis A-G),
  • have undergone previous wound care therapy that included any bioengineered alternative tissue or STSG 30 days prior to enrollment
  • pregnant
  • enrolled in any other interventional clinical research trial
  • an increase or decrease of more than 25% in wound area or volume from the Screening to Baseline visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    DermACELL AWM

    Human acellular dermal matrix (ADM) recovered from human donors, decellularized, provided with at least 97% DNA removal, terminally sterilized in its final package, and ready to use.

    Other: DermACELL AWM

Interventions

  • OtherDermACELL AWM

    Decellularized regenerative human tissue matrix allograft (dermis) processed using proprietary Matracell® technology

06

What researchers measure

Primary outcomes

  1. Time (days) required for wound bed preparation (granular bed after placement of DermACELL AWM).

    Days required for granular bed formation

    Time frame: 112 Days

Secondary outcomes

  1. Number of applications of study product required to achieve granulation.

    Time frame: 16 Weeks

  2. Percent wound area reduction and percent complete wound closure at 16 Weeks.

    Time frame: 16 Weeks

  3. The number of adverse events after DermACELL AWM application including infection, hospitalization, and reoperation.

    Time frame: 16 Weeks

07

Study locations

2 sites
  • Limb Preservation Platform
    Fresno, California 93710, United States
  • Purvis Moyer Foot and Ankle Center
    Rocky Mount, North Carolina 27804, United States
08

References and documents

Publications

  • Cazzell S, Moyer PM, Samsell B, Dorsch K, McLean J, Moore MA. A Prospective, Multicenter, Single-Arm Clinical Trial for Treatment of Complex Diabetic Foot Ulcers with Deep Exposure Using Acellular Dermal Matrix. Adv Skin Wound Care. 2019 Sep;32(9):409-415. doi: 10.1097/01.ASW.0000569132.38449.c0. PubMed 31361269 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Apr 2018, 15 months.

Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 15 months is below that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2017
First posted
Feb 6, 2017
StartActual
Jan 15, 2017
Primary completionActual
Apr 30, 2018
CompletionActual
Dec 31, 2018
Last update
Sep 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03044132
Lead sponsor
LifeNet Health
Responsible party
Sponsor
First posted
Feb 6, 2017
Start date
Jan 15, 2017
Primary completion
Apr 30, 2018
Completion
Dec 31, 2018
Last update
Sep 6, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion